Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

, MYL

Mylan

$35.94

-0.9 (-2.44%)

09:40
10/10/16
10/10
09:40
10/10/16
09:40

Unusually active option classes on open October 10th

Unusual total active option classes on open include: Exelixis (EXEL), Mylan (MYL), Salesforce.com (CRM), Las Vegas Sands (LVS), Caterpillar (CAT), Diamond ETF (DIA), and AT&T (T).

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

MYL

Mylan

$35.94

-0.9 (-2.44%)

CRM

Salesforce

LVS

Las Vegas Sands

CAT

Caterpillar

DIA

Diamonds Fund ETF

T

AT&T

  • 10

    Oct

  • 10

    Oct

  • 24

    Oct

  • 09

    Nov

  • 28

    Mar

EXEL Exelixis
$12.95

-0.23 (-1.75%)

10/10/16
PIPR
10/10/16
UPGRADE
PIPR
Overweight
Exelixis upgraded to Overweight from Neutral at Piper Jaffray
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink says ESMO raises confidence in potential label expansions at Exelixis
Following several oral and poster presentations this weekend at the ESMO cancer meeting, Leerink analyst Michael Schmidt said he has greater confidence regarding several potential label expansion opportunities for Exelixis' two products, Cabometyx and Cotellic. Cabometyx is "very well positioned" to capture significant market share and consensus expectations for Cotellic are only modest, believes Schmidt, who keeps an Outperform rating on Exelixis shares.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.
10/10/16
PIPR
10/10/16
UPGRADE
Target $21
PIPR
Overweight
Exelixis upgraded to Overweight after trial success at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff upgraded Exelixis to Overweight from Neutral after the company reported Phase II CABOSUN data in 157 front-line metastatic Renal Cell Carcinoma patients. The data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use, Tenthoff tells investors in a research note. The analyst raised his price target for the shares to $21 from $8.
MYL Mylan
$35.94

-0.9 (-2.44%)

10/10/16
UBSW
10/10/16
NO CHANGE
Target $60
UBSW
Buy
UBS remains constructive on Mylan despite governance controversy
UBS analyst Marc Goodman said he remains constructive on Mylan despite the controversy surrounding its corporate governance. Goodman cited the company's ability to execute, its surprise announcement of a EpiPen Medicaid lawsuit settlement and its updated guidance, which was better than feared. Goodman reiterated his Buy rating and lowered his price target to $60 from $66 on Mylan shares.
10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
CRM Salesforce

10/07/16
PIPR
10/07/16
NO CHANGE
Target $100
PIPR
Overweight
Piper sees 'clouds parting' on Salesforce valuation
Salesforce CEO Marc Benioff mostly calmed nerves over a potential Twitter (TWTR) acquisition by saying at the company's analyst day, "While we look at everything, we pass on almost everything," Piper Jaffray analyst Alex Zukin tells investors in a research note. The comment does not completely take a deal for Twitter off the table, but the probability of a transformational acquisition is now "dramatically lower," Zukin contends. As such, the analyst feels the "clouds are parting" on Salesforce's valuation "with sunshine ahead." Zukin believes the company has a "clear line of sight" to $10B in revenue in FY17. He keeps an Overweight rating on the shares with a $100 price target. Salesforce closed yesterday up $2.84, or 4%, to $71.26.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees 'opportune entry point' for Salesforce
JPMorgan analyst Mark Murphy believes shares of Salesforce (CRM) are at an "'opportune entry point" following the recent selloff. The pullback has been driven by a "slightly soft" Q2 and concerns about a potentially expensive acquisition of Twitter (TWTR), Murphy tells investors in a research note. After speaking to industry contacts at Dreamforce, the analyst sees a path for the "overhangs to fade" with a "better pace of business in Q3/Q4" as well as the eventual fading of the Twitter discussion. Murphy reiterates an Overweight rating on Salesforce with a $95 price target in a research note titled "The Most Valuable Cloud Asset Is Undeservedly Undervalued."
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
10/07/16
ADAM
10/07/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce worthy of investor consideration at current levels, says Canaccord
Canaccord analyst Richard Davis came away from the Salesforce (CRM) Dreamforce week more enthused about the company's outlook. The analyst noted the company is growing its revenues 3.5 times faster than it legacy peers. Davis noted the company's CEO said they are very disciplined on price when it comes to acquisitions and believes that they would not be interested in Twitter (TWTR) at its rumored asking price of $28 per share. Davis reiterated his Buy rating and $95 price target on Salesforce shares.
LVS Las Vegas Sands

09/14/16
ARGS
09/14/16
UPGRADE
ARGS
Buy
Las Vegas Sands upgraded on Macau outlook at Argus
As noted earlier, Argus upgraded Las Vegas Sands to Buy from Hold. Analyst John Staszak notes that Macau gross gaming revenue increased year-over-year last month for the first time in over two years. He says that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. Target $67.
09/14/16
09/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying an attractive free cash flow and dividend yield makes the risk/reward attractive at current levels. 2. Fifth Third (FITB) upgraded to Buy from Neutral at Compass Point. 3. F5 Networks (FFIV) upgraded to Outperform from Perform at Oppenheimer with analyst Ittai Kidron saying the company has several potential drivers that could drive year-over-year product revenue growth back into positive territory in fiscal 2017. 4. Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus with analyst John Staszak saying that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. 5. DeVry (DV) upgraded to Outperform from Market Perform at Barrington with analyst Alexander Paris saying management's near-term goal is stabilizing revenue at DeVry University growing enrollment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
BOFA
10/04/16
UPGRADE
BOFA
Buy
Las Vegas Sands upgraded to Buy from Neutral at BofA/Merrill
10/04/16
BOFA
10/04/16
UPGRADE
Target $63
BOFA
Buy
Las Vegas Sands upgraded on expected estimate revisions at BofA/Merrill
BofA/Merrill analyst Shaun Kelley upgraded Las Vegas Sands to Buy and raised its price target to $63 from $52. The analyst said shares remain fairly under-owned and thinks estimate revisions will move higher due to market momentum, better ROI for Parisian, Cotai infrastructure additions, and optionality from Japan and real estate.
CAT Caterpillar

09/19/16
09/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Hold from Buy at Canaccord with analyst Michael Graham saying he expects TPV growth to remain solid driven by Venmo and One Touch, but said these factors are well understood and reflected in estimates. 2. Viacom (VIA, VIAB) downgraded to Hold from Buy at Stifel with analyst Benjamin Mogil saying the stock's valuation is no longer attractive in the wake of the news that the company had decided to table its plans to sell a minority stake in Paramount. 3. Caterpillar (CAT) downgraded to Mixed from Positive at OTR Global with the firm saying third quarter global new heavy equipment orders are down 8%-11% year-over-year on weakness in North American. 4. Western Union (WU) downgraded to Negative from Neutral at Susquehanna with analyst James Friedman saying he is concerned about downside risks given the company's high multiple, increased regulatory scrutiny, and the lack of improvement in its Middle East business. 5. Campbell Soup (CPB) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/16
OTRG
09/19/16
DOWNGRADE
OTRG
Mixed
Caterpillar downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Caterpillar to Mixed saying Q3 global new heavy equipment orders are down 8-11% year-over-year on weakness in North American. The firm said EMEA North American used equipment availability is looser and dealers expect further used pricing pressures as large volumes of leased machines are returned to Caterpillar Financial.
09/07/16
09/07/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Navistar (NAV) initiated with a Hold at Deutsche Bank. 2. Barrick Gold (ABX) initiated with a Sell at Berenberg while the firm initiated Randgold (GOLD), Kinross Gold (KGC), and Goldcorp (GG) with a Hold. 3. 3. After the close on Tuesday, Deutsche Bank analysts Nicole DeBlase, Saree Boroditsky, and Kevin Marek initiated the U.S. Machinery group with a "cautious view." Oshkosh (OSK), Caterpillar (CAT), and Wabtec (WAB) were initiated with Buy ratings at Deutsche Bank, while the firm initiated Cummins (CMI) and CNH Industrial (CNHI) with Sell ratings. The firm also initiated Deere (DE), AGCO (AGCO), Terex (TEX), PACCAR (PCAR), WABCO (WBC), and United Rentals (URI) with Hold ratings. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/16
DBAB
09/06/16
INITIATION
DBAB
Deutsche Bank starts U.S. Machinery group with 'cautious view'
Deutsche Bank analysts Nicole DeBlase, Saree Boroditsky, and Kevin Marek initiated the U.S. Machinery group with a "cautious view." While the analysts see the natural resource markets as having bottomed, they also only expect "low-single digit industry organic growth through 2020." The team's top pick is Caterpillar (CAT), and they are also positive on Oshkosh Corp (OSK) and Wabtec (WAB), all of which are Buy rated, but are negative on CNH Industrial (CNHI) and Cummins (CMI), which are Sell rated.
DIA Diamonds Fund ETF

T AT&T

10/06/16
FBNS
10/06/16
INITIATION
Target $69.24
FBNS
Outperform
AMC Networks initiated with an Outperform at FBN Securities
FBN Securities analyst Robert Routh initiated AMC Networks (AMCX) with an Outperform rating and a fair value estimate of $69.24. Routh calls AMC Networks "very attractive" as a possible takeover target, as he believes it could fit well with either the soon-to-be-combined Lionsgate (LGF)-Starz (STRZA) or with AT&T's (T) DTV division. Routh added that reports have indicated that AT&T is looking to grow its portfolio of TV content through deals.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
UBSW
09/28/16
DOWNGRADE
Target $43
UBSW
Neutral
AT&T downgraded to Neutral from Buy at UBS
UBS analyst John Hodulik downgraded AT&T to Neutral citing expectations for lower earnings growth. The analyst reduced his earnings estimates by 3% to reflect the "increased competitive intensity" in wireless and incremental costs associated with AT&T's DTV Now roll-out. Hodulik cut his price target for AT&T shares to $43 from $46.
09/26/16
09/26/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Hold from Reduce at HSBC. 2. Potash (POT) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson citing expected benefits from the company's proposed merger with Agrium (AGU), which he sees as having relatively low antitrust risk compared to the other mega-mergers being pursued in the Ag space. 3. Oshkosh (OSK) upgraded to Overweight from Neutral at JPMorgan and to Neutral from Underperform at Credit Suisse. 4. Marriott (MAR) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Thomas Allen citing strong unit growth. 5. NetApp (NTAP) upgraded to Buy from Hold at Cross Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PDCE

PDC Energy

$44.72

2.21 (5.20%)

13:22
06/26/17
06/26
13:22
06/26/17
13:22
Hot Stocks
Department of Justice, Colorado file civil complaint against PDC Energy »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

13:20
06/26/17
06/26
13:20
06/26/17
13:20
Options
Call buyer opens a notable new position in 20th Century Fox »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

, MSFT

Microsoft

$71.21

0.95 (1.35%)

13:19
06/26/17
06/26
13:19
06/26/17
13:19
Hot Stocks
Facebook, Twitter, Microsoft, YouTube form global forum to counter terrorism »

Facebook (FB), Microsoft…

FB

Facebook

$155.07

1.67 (1.09%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

TWTR

Twitter

$18.35

-0.155 (-0.84%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

$NSD

NASDAQ Market Internals

13:17
06/26/17
06/26
13:17
06/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/26/17
06/26
13:16
06/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

, SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Technical Analysis
Technical View: S&P 500 chart view at mid-session »

The small bearish price…

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$13.68

-0.12 (-0.87%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Options
Goldcorp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KR

Kroger

$22.58

-0.02 (-0.09%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Hot Stocks
Kroger executive VP Schlotman acquires 2,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
06/26/17
06/26
13:15
06/26/17
13:15
General news
Treasury's $26 B 2-year sale was well received, as expected »

Treasury's $26 B…

DB

Deutsche Bank

$16.89

0.25 (1.50%)

13:12
06/26/17
06/26
13:12
06/26/17
13:12
Periodicals
Deutsche Bank's chief U.S. economist LaVorgna steps down, Bloomberg reports »

Joe LaVorgna, a chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

WDC

Western Digital

$93.34

3.09 (3.42%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

13:11
06/26/17
06/26
13:11
06/26/17
13:11
Periodicals
Toshiba near sale of memory chip unit to consortium, Nikkei reports »

Toshiba (TOSYY) could…

WDC

Western Digital

$93.34

3.09 (3.42%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$146.28

0.65 (0.45%)

13:09
06/26/17
06/26
13:09
06/26/17
13:09
Hot Stocks
Apple CEO: 'Inspired' by Indian PM Modi's vision »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZIXI

ZixCorp

$5.77

-0.06 (-1.03%)

13:05
06/26/17
06/26
13:05
06/26/17
13:05
Hot Stocks
Breaking Hot Stocks news story on ZixCorp »

ETF Managers reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$28.97

-0.29 (-0.99%)

12:58
06/26/17
06/26
12:58
06/26/17
12:58
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Novo Holdings cuts Reata…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

HSTM

HealthStream

$30.89

0.72 (2.39%)

12:57
06/26/17
06/26
12:57
06/26/17
12:57
Recommendations
HealthStream analyst commentary  »

HealthStream contract end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Treasury 2-year auction preview: the sale should see decent results »

Treasury 2-year auction…

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Breaking General news story  »

San Francisco Federal…

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

12:46
06/26/17
06/26
12:46
06/26/17
12:46
Hot Stocks
Amazon CEO: Excited to keep investing in India »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

12:43
06/26/17
06/26
12:43
06/26/17
12:43
Periodicals
EU to likely hit Google with record fine in antitrust case, Reuters says »

EU antitrust authorities…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NURO

NeuroMetrix

$2.95

0.06 (2.08%)

12:39
06/26/17
06/26
12:39
06/26/17
12:39
Hot Stocks
NeuroMetrix names Xuan Kong as Chief Data Scientist »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$17.41

-0.13 (-0.74%)

12:38
06/26/17
06/26
12:38
06/26/17
12:38
Periodicals
Snap taps Internet Association's Woodworth for public policy team, Recode says »

Recode's Tony Romm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

DEO

Diageo

$120.05

0.7915 (0.66%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Upgrade
Diageo rating change  »

Diageo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Periodicals
Two bidders remain in Toshiba's Landis+Gyr auction, Reuters reports »

The group of prospective…

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

GS

Goldman Sachs

$219.98

2.79 (1.28%)

ONEXF

Onex

$77.08

1.32 (1.74%)

HTHIY

Hitachi

$60.70

0.32 (0.53%)

HON

Honeywell

$134.27

0.28 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 21

    Jul

  • 26

    Jul

  • 30

    Jul

  • 17

    Oct

CC

Chemours

$36.20

0.2 (0.56%)

12:34
06/26/17
06/26
12:34
06/26/17
12:34
Hot Stocks
Chemours announces groundbreaking for mining solutions manufacturing facility »

The Chemours Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$81.32

-0.29 (-0.36%)

12:30
06/26/17
06/26
12:30
06/26/17
12:30
Options
$1.5M premium block in Exxon options »

$1.5M premium block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.